Amedica Corporation (NASDAQ: AMDA) is having an overwhelmingly strong start to the trading session this morning, following up on the tremendous gains the stock saw yesterday. The gains are ultimately the result of the company’s announcement of its first successful spine fusion surgery. Of course, the news excited investors, which is continuing to send the stock upward. Today, we’ll talk about:
- The surgery;
- what we’re seeing from AMDA as a result; and
- what we’ll be watching for ahead
AMDA Announces First Successful Spinal Fusion
As mentioned above, Amedica Corporation is having an incredibly strong start to the trading session, following up on gains that were experienced yesterday. These gains are ultimately the result of a press release yesterdy in which the company announced the first successful completion of a spine fusion surgery using the Valeo C+CSC with Lumen Interbody Fusion Device.
This device is was developed by AMDA and is the company’s newest spinal implant device. The device received FDA clearance earlier this year. It is a composit silicon nitride implant that combines different densities of the company’s proprietary medical grade silicon and nitride ceramic.
In a statement, Dr. Tarek Elalayli, the doctor that performed the surgery, had the following to offer:
The implant, consisting of a novel combination of solid and porous silicon nitride, is well-designed, and the surgical implantation was straight forward. The benefits of this new device include the potential for bone in-growth as well as on-growth, while a central lumen gives the surgeon flexibility to add bone graft, if needed. The device and underlying technology are a step toward spine fusion without the need for bone graft additives; with the advantages of good radiographic visualization, and inherent antibacterial properties of silicon nitride. No other spinal fusion implant combines all these properties.
The above statement was followed up by Dr. Sonny Bal, Chairman at AMDA. Here’s what he had to offer:
Several of our published reports have challenged the existing dogma that the surface texture of a biomaterial alone affects bone healing. Instead, we have shown that surface microchemistry also plays a critically important role in promoting bone healing. In the case of silicon nitride, we can precisely engineer both the surface nanostructure, as well as the surface microchemistry of an implant in order to stimulate bone-forming cells, speed up bone fusion, and discourage bacterial adhesion. The Valeo C+CsC with Lumen device captures these advantages by manufacturing different material densities into one smart, bioactive implant that is already optimized for spinal fusion. In contrast, competing implants made of inert metal and plastic usually require enhancement with cost-added bone fillers, surface texturing, or related gimmicks… Unlike any other biomaterial available for spinal fusion today, silicon nitride is in a class by itself.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to dig into the market is that the news leads to moves. In the case of Amedica, the news proved to be overwhelmingly positive. After all, the first successful spinal fusion will likely open the door to more, and each one drives revenue for the company. So, it comes as no surprise that excited investors are sending the stock toward the top. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (10:35), AMDA is trading at $0.52 per share after a gain of $0.038 per share or 7.70% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on AMDA. In particular, we’re interested in following the story surrounding the company’s newly approved spinal fusion device its growth as a treatment option for consumers with severe back injuries. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!